AMBITION (High Dose AMBISOME on a Fluconazole Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Randomised Controlled Non-inferiority Trial) is a four-year project funded at €10M by the European and Developing Countries Clinical Trials Partnership, the Swedish International Development Agency and the DFID/MRC/Wellcome Trust Joint Global Health Trials Fund. It runs from 1 January 2017 – 31 December 2020 across a consortium of six African and five European partners.
The Phase III clinical trial (AMBITION-cm) is the largest clinical trial for HIV-associated cryptococcal meningitis ever to be conducted. Recruitment of 850 participants is underway and will conclude in 2021.
A number of other activities run alongside the trial, including economic cost-effectiveness analyses, laboratory-based sub-studies and capacity building events. AMNET (African Meningitis Network) has been established to provide a solid framework to facilitate future clinical trials to investigate urgently-needed novel treatments and diagnostics strategies aimed at reducing the morbidity and mortality due to meningitis in Africa. AMNET will continue to develop well after the conclusion of the AMBITION study.
AMBITION is co-ordinated by The London School of Hygiene and Tropical Medicine, UK. African collaborating institutions (where participants will be recruited) are shown below.
The AMBITION consortium is extremely grateful to the following funders:
- The European and Developing Countries Clinical Trials Partnership (EDCTP)
- The Swedish International Development Agency
- The DFID/MRC/Wellcome Trust Joint Global Health Trials Scheme
…and to Gilead, who has donated the AmBisome for the clinical trial.